Eli Lilly says it is taking legal action against companies selling retatrutide, an experimental weight-loss drug that is not yet approved. The company plans to file lawsuits against six outlets, according to multiple reports, while also asking regulators to increase oversight and enforcement against what it describes as an illicit market.
Lilly’s approach targets businesses that it alleges are offering retatrutide products illegally, rather than through authorized channels. The reports also note that Lilly is urging government regulators to do more to rein in the black market, framing the effort as both a court and regulatory response to prevent misuse and unauthorized distribution.
Across the outlets, the main details align: Lilly is contesting sales activity tied to retatrutide, the drug remains unapproved, and the company is pursuing both litigation against specific sellers and additional action from regulators.
